<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426047</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00038562</org_study_id>
    <nct_id>NCT02426047</nct_id>
  </id_info>
  <brief_title>Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy</brief_title>
  <official_title>The Feasibility and Tolerability of Medium Chain Triglycerides as an Adjunct to the Dietary Management of Epilepsy in Women With a Catamenial Seizure Pattern on the Modified Atkins Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vitaflo International, Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The modified Atkins diet (MAD) has been shown to be effective in treating intractable&#xD;
      epilepsy. Approximately 55% of the patients started on the diet are women of childbearing age&#xD;
      and women with epilepsy often have a pattern of seizures that correlates with their menstrual&#xD;
      cycle, called catamenial epilepsy. The investigators have observed that despite an overall&#xD;
      reduction in seizure frequency, some women on the MAD continue to have breakthrough seizures&#xD;
      in a catamenial pattern. The investigators hypothesize that women with a history of&#xD;
      intractable epilepsy who have been on the modified Atkins diet for at least 3 months and have&#xD;
      a catamenial seizure pattern will tolerate and be compliant with the addition of a daily&#xD;
      amount of betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time&#xD;
      interval starting 2 days prior to and encompassing the primary catamenial pattern.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance as measured by the percent of time the participants drinks betaquik® averaged over 3 months</measure>
    <time_frame>6 months</time_frame>
    <description>The primary outcome measure will be compliance with betaquik® (compared to published compliance of MAD and medium chain triglyceride diets) to demonstrate feasibility. The participant will be considered compliant if they drink the required amount of betaquik® on more than 80% of the prescribed days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability (10 point tolerance scale)</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary outcome measures will be tolerability of betaquik® based on a 10 point tolerance scale.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Epilepsy</condition>
  <condition>Seizure</condition>
  <condition>Catamenial Epilepsy</condition>
  <condition>Medically Resistant Epilepsy</condition>
  <condition>Medically Resistant Seizures</condition>
  <arm_group>
    <arm_group_label>Modified Atkins diet plus betaquik®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue on the modified Atkins diet (with a 20 net grams carbohydrate per day limit) and add betaquik® (a liquid emulsion of medium chain triglycerides) for 10 days per month for 5 months. The days chosen are based on their particular catamenial pattern (there are 3 types that have been identified in the literature).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>betaquik®</intervention_name>
    <description>Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.</description>
    <arm_group_label>Modified Atkins diet plus betaquik®</arm_group_label>
    <other_name>betaquik</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult women ≥ 18 years&#xD;
&#xD;
          -  Already on the modified Atkins diet for at least 3 months and compliant with treatment&#xD;
&#xD;
          -  Catamenial seizure pattern (by Herzog criteria) for at least 2 of the past 3 months&#xD;
             (as documented by calendars provided with annotations for seizures and menstrual cycle&#xD;
             start and end dates)&#xD;
&#xD;
        Exclusion Criteria (basic exclusion criteria for the modified Atkins diet, so patients&#xD;
        should have already been screened for these factors):&#xD;
&#xD;
          -  Unwilling to restrict carbohydrates&#xD;
&#xD;
          -  Significantly underweight (BMI &lt;18.5)&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  History of hypercholesterolemia (&gt;300 mg/dl) or hypertriglyceridemia (&gt;200 mg/dl)&#xD;
&#xD;
          -  Metabolic or mitochondrial disorder&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactose intolerance or milk allergy&#xD;
&#xD;
          -  Aversion to liquids or inability to eat solid food&#xD;
&#xD;
        Exclusion Criteria (specific to this study):&#xD;
&#xD;
          -  Men&#xD;
&#xD;
          -  Women who are menopausal or peri-menopausal&#xD;
&#xD;
          -  Prior use of betaquik® at any time for any duration&#xD;
&#xD;
          -  Already using another ketogenic diet supplement on a sporadic basis (unless the&#xD;
             patient is using one daily and is willing to continue doing so for the duration of&#xD;
             this study)&#xD;
&#xD;
          -  Already using coconut oil specifically for catamenial epilepsy within the month prior&#xD;
             to enrollment (okay if patient only using for cooking throughout the month)&#xD;
&#xD;
          -  Taking a hormonal contraceptive so that they do not menstruate (e.g. taking active&#xD;
             instead of placebo oral contraceptive pills to avoid having a period)&#xD;
&#xD;
          -  Anticipated need to adjust anti-epileptic medications within the next 6 months&#xD;
&#xD;
          -  Anticipated initiation, change, or discontinuation of a hormonal contraceptive within&#xD;
             the next 6 months&#xD;
&#xD;
          -  Pregnant or anticipated pregnancy within the next 6 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mackenzie C Cervenka, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital &amp; Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kossoff EH, Rowley H, Sinha SR, Vining EP. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia. 2008 Feb;49(2):316-9. Epub 2007 Oct 5.</citation>
    <PMID>17919301</PMID>
  </reference>
  <reference>
    <citation>Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997 Oct;38(10):1082-8.</citation>
    <PMID>9579954</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seizures</keyword>
  <keyword>epilepsy</keyword>
  <keyword>catamenial</keyword>
  <keyword>ketogenic diet</keyword>
  <keyword>modified Atkins diet</keyword>
  <keyword>intractable epilepsy</keyword>
  <keyword>medically refractory epilepsy</keyword>
  <keyword>adult</keyword>
  <keyword>medium chain triglyceride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

